Business Context and Reporting Period
Company: Daxor Corporation (DXR)
Filing Type: Form 8-K (Current Report)
Date of Report: October 27, 2023
Principal Office: Oak Ridge, TN
Context: The filing provides an update on the allocation of proceeds from a public offering completed on May 22, 2023.
Key Financial Metrics
Capital Raised: Net proceeds of $3,555,532 from the issuance of 410,260 shares at $9.75 per share.
Allocated Funds: $1,900,000 reserved from the net proceeds.
Other Metrics: The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the specific designation of funds. The Company has formally reserved $1,900,000 of the net proceeds from the May 2023 offering to support the continued development of its next-generation optical blood volume analyzer systems.
Outlook and Management Commentary
- Development Timeline: The Company anticipates the development work will proceed over a 24-month period.
- Strategic Partnership: Development is expected to be conducted in conjunction with other technology development efforts supported by the Department of Defense.
- Management Sentiment: Management expressed excitement regarding the advancement of next-generation technologies.
- Risks and Contingencies: The filing text does not provide a clear value for specific risks or contingencies beyond the general nature of technology development.
Investor Verification Checklist
- Verify the total net proceeds of $3,555,532 and the share count of 410,260 from the May 22, 2023 offering.
- Confirm the specific allocation of $1,900,000 toward optical blood volume analyzer systems.
- Review the Prospectus Supplement filed on May 23, 2023, for full details on the offering.
- Monitor future filings for updates on the 24-month development timeline and Department of Defense collaboration status.